|
Early
|
hsa04080:Neuroactive ligand-receptor interaction
|
9
|
4.71
|
1.35E-03
|
HTR1A,S1PR5,HTR7,GIPR,GRIK4,P2RY6,MTNR1B,GABBR1,ADRB1
|
|
hsa00150:Androgen and estrogen metabolism
|
3
|
1.57
|
4.02E-02
|
LCMT2,SRD5A3,SULT2B1
|
|
hsa00140:Steroid hormone biosynthesis
|
3
|
1.57
|
5.96E-02
|
CYP1B1,SRD5A3,SULT2B1
|
|
Middle
|
hsa04020:Calcium signaling pathway
|
6
|
2.87
|
2.61E-02
|
TNNC2,AVPR1A,ITPR3,PDE1C,BST1,ADRB3
|
|
hsa05200:Pathways in cancer
|
7
|
3.35
|
9.31E-02
|
RARA,SHH,GSTP1,PAX8,WNT10B,MMP9,APC2
|
|
hsa05217:Basal cell carcinoma
|
3
|
1.44
|
9.79E-02
|
SHH,WNT10B,APC2
|
|
hsa04080:Neuroactive ligand-receptor interaction
|
6
|
2.87
|
9.82E-02
|
GPR35,AVPR1A,NPBWR1,VIPR1,ADRB3,S1PR5
|
|
Late
|
hsa04080:Neuroactive ligand-receptor interaction
|
9
|
3.9
|
1.15E-03
|
HTR2C,GABRG3,MLNR,GPR83,ADRA1A,S1PR4,GALR2,ADORA3,ADRB3
|
|
hsa05200:Pathways in cancer
|
8
|
3.46
|
1.88E-02
|
FGF8,CDKN2A,WNT10A,RET,SPI1,BMP2,MMP9,BCR
|
